114 related articles for article (PubMed ID: 25161160)
1. Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.
Kim HS; Oh M; Kim EJ; Song GS; Ghim JL; Shon JH; Kim DH; Shin JG
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):1005-11. PubMed ID: 25161160
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin.
Choi HK; Oh M; Kim EJ; Song GS; Ghim JL; Shon JH; Kim HS; Shin JG
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):147-53. PubMed ID: 25546164
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of voglibose administered alone, administered with metformin, and administered with metformin in a fixed-dose combination in healthy Korean subjects
.
Kim HS; Oh M; Kim EJ; Song GS; Kim EY; Shin JG
Int J Clin Pharmacol Ther; 2018 Nov; 56(11):544-550. PubMed ID: 30178742
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
[TBL] [Abstract][Full Text] [Related]
8. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
9. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.
Kleist P; Ehrlich A; Suzuki Y; Timmer W; Wetzelsberger N; Lücker PW; Fuder H
Eur J Clin Pharmacol; 1997; 53(2):149-52. PubMed ID: 9403288
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
Li J; Klemm K; O'Farrell AM; Guler HP; Cherrington JM; Schwartz S; Boyea T
Curr Med Res Opin; 2010 Aug; 26(8):2003-10. PubMed ID: 20583949
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
[TBL] [Abstract][Full Text] [Related]
13. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
14. Effects of Food Thickeners on the Inhibitory Effect of Voglibose Oral-disintegrating Tablets on Post-prandial Elevation of Blood Sugar Levels.
Tomita T; Goto H; Sumiya K; Yoshida T; Tanaka K; Kohda Y
Yakugaku Zasshi; 2016; 136(8):1171-6. PubMed ID: 27477734
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
16. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin.
Fuder H; Kleist P; Birkel M; Ehrlich A; Emeklibas S; Maslak W; Stridde E; Wetzelsberger N; Wieckhorst G; Lücker PW
Eur J Clin Pharmacol; 1997; 53(2):153-7. PubMed ID: 9403289
[TBL] [Abstract][Full Text] [Related]
17. A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers.
Noh YH; Lim HS; Jung JA; Jin SJ; Kim MJ; Kim YH; Park HJ; Bae KS
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):605-13. PubMed ID: 22762856
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
Macha S; Dieterich S; Mattheus M; Seman LJ; Broedl UC; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):132-40. PubMed ID: 23253948
[TBL] [Abstract][Full Text] [Related]
20. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
